- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07489651
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder
The purpose of this study is to determine if treatment with a single and/or repeat dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Mark Pollack Chief Medical Officer, M.D.
- Phone Number: 1-888-880-REUN
- Email: info@reunionneuro.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Recruiting
- University of Alabama (UAB) Clinical Research Unit (CRU)
-
Contact:
- Seher Premani
- Phone Number: spremani@uab.edu
- Email: spremani@uab.edu
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Recruiting
- Lighthouse Psychiatry
-
Contact:
- Matt Longson
- Phone Number: 435-268-5800
- Email: Contact@neosciclinicalresearch.com
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72211
- Recruiting
- Preferred Research Partners, Inc.
-
Contact:
- Stacy Tierney
- Phone Number: 111 501-553-9987
- Email: stierney@preferredresearchpartners.com
-
-
California
-
Garden Grove, California, United States, 92845
- Recruiting
- Collaborative Neuroscience Research, LLC
-
Contact:
- CNS Outreach Department
- Phone Number: 844-424-9494
- Email: cns.outreach@cenexel.com
-
La Jolla, California, United States, 92037
- Recruiting
- Kadima Neuropsychiatry Institute
-
Contact:
- Angelica Lu
- Phone Number: 858-775-2053
- Email: angelical@kadimanp.com
-
San Francisco, California, United States, 94114
- Recruiting
- Open Mind Therapeutics
-
Contact:
- Victoria Vega
- Phone Number: 415-906-7399
- Email: victoria@openmindcollective.org
-
Santa Monica, California, United States, 90404
- Recruiting
- TRIP Clinic at Psychedelic Science Institute
-
Contact:
- Ashley Ramos
- Email: trialadmin@psychedlicsci.com
-
-
Florida
-
Lauderhill, Florida, United States, 33319
- Recruiting
- Innovative Clinical Research, Inc.
-
Contact:
- Melissa Rodco
- Phone Number: 305-722-8444
- Email: mrodco@segaltrials.com
-
Tampa, Florida, United States, 33613
- Recruiting
- University of South Florida
-
Contact:
- Genesis Estramera
- Phone Number: 813-974-1404
- Email: gestramera@usf.edu
-
-
Georgia
-
Atlanta, Georgia, United States, 30331
- Recruiting
- Atlanta Center for Medical Research
-
Contact:
- Amber Tannahill
- Phone Number: 404-881-5800
- Email: a.tannahill@cenexel.com
-
Decatur, Georgia, United States, 30030
- Recruiting
- CenExel iResearch, LLC
-
Contact:
- Michael Mahaffrey
- Email: m.mahaffrey@cenexel.com
-
Norcross, Georgia, United States, 30092
- Recruiting
- Evergreen Clinical Trials
-
Contact:
- Stephen Wheeler
- Phone Number: 943-230-1385
- Email: stephen@evergreenstrials.com
-
Savannah, Georgia, United States, 31405
- Recruiting
- CenExel iResearch, LLC
-
Contact:
- Michelle Lagares
- Phone Number: 912-744-0800
- Email: M.Lagares@CenExel.com
-
-
Illinois
-
Chicago, Illinois, United States, 60640
- Recruiting
- Uptown Research Institute
-
Contact:
- Deborah Jones-Miller
- Phone Number: 117 773-989-8313
- Email: Djones-miller@uptownresearch.com
-
-
Michigan
-
Novi, Michigan, United States, 48377
- Recruiting
- Henry Ford Medical Center - Columbus
-
Contact:
- Madeline Bross
- Phone Number: 248-344-7366
- Email: mbross1@hfhs.org
-
-
Missouri
-
Saint Charles, Missouri, United States, 63304
- Recruiting
- Midwest Research Group
-
Contact:
- Lindsay vanWinkle
- Phone Number: 3 636-946-8032
- Email: lvanwinkle@midwestresearchgroup.com
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 14624
- Recruiting
- UNM Research Program Psychedelic Therapies
-
Contact:
- Hector Garcia
- Phone Number: 505-675-0582
- Email: hecgarcia@salud.unm.edu
-
-
New York
-
New York, New York, United States, 10016
- Recruiting
- NYU-H+C Clinical and Translational Science Institute
-
Contact:
- Jillian Kelly
- Phone Number: 212-404-7764
- Email: Jillian.kelly@nyulangone.org
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Recruiting
- University of North Carolina at Chapel Hill
-
Contact:
- Julia Hoffman
- Email: julia_hoffmann1@med.unc.edu
-
-
Ohio
-
North Canton, Ohio, United States, 44720
- Recruiting
- Neuro-Behavioral Clinical Research, Inc.
-
Contact:
- Crystal Blackford
- Phone Number: 330-493-1118
- Email: cblackford@nb-cr.com
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Recruiting
- Summit Headlands LLC
-
Contact:
- Tyler Leecing
- Email: tyler.leecing@summitnetwork.com
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
Contact:
- Erin Blase
- Phone Number: 215-746-6419
- Email: erin.blase@pennmedicine.upenn.edu
-
West Chester, Pennsylvania, United States, 19380
- Withdrawn
- Suburban Research Associates
-
-
Texas
-
Austin, Texas, United States, 78737
- Recruiting
- Austin Clinical Trial Partners
-
Contact:
- Kara Chilek
- Phone Number: 512-521-0595
- Email: studyinfo@austinCTP.com
-
Austin, Texas, United States, 78759
- Recruiting
- BioBehavioral Research Austion
-
Contact:
- Tracie Wesson
- Phone Number: 402-934-0044
- Email: tracie.wesson@qcrnetwork.com
-
Plano, Texas, United States, 75093
- Recruiting
- Aim Trials, LLC
-
Contact:
- Sonia Prashar
- Phone Number: 214-856-2778
- Email: sonia.prashar@aimtrials.com
-
-
Utah
-
Draper, Utah, United States, 84020
- Recruiting
- Cedar Clinical Research
-
Contact:
- Jane Bjorklund
- Phone Number: 801-369-4219
- Email: jane.bjorklund@numinusnetwork.com
-
Orem, Utah, United States, 84058
- Recruiting
- Inner Space State Street
-
Contact:
- Janet Jimenez
- Phone Number: 801-871-5516
- Email: apply@innerspaceresearch.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has Generalized Anxiety Disorder as defined by DSM-5-TR
- If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant.
- Is willing and able to comply with the conditions and requirements of the study
Exclusion Criteria:
- Has a significant risk of suicide
- Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
- Has other concurrent psychiatric disorders that is the primary disorder.
- Has other medically significant conditions rendering unsuitability for the study
- Has used or will need to use prohibited medications or therapies
- Has a known sensitivity or intolerance to study intervention or potential rescue medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
A single subcutaneous injection of 0.9% sodium chloride for injection per dosing session |
Single-dose (Part A) or Repeat-dose (Part B), subcutaneous injection(s) of 0.9% sodium chloride for injection |
|
Experimental: 30 mg RE104
A single subcutaneous injection of 30 mg RE104 for Injection per dosing session |
Single dose (Part A) or Repeat-dose (Part B), subcutaneous injection(s) of RE104 for Injection |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
RE104 when administered as a single 30 mg dose or as two 30 mg doses 3 weeks apart versus placebo change from Baseline at Week 4 in Hamilton Anxiety Rating Scale (HAM-A) total score
Time Frame: Week 4
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
RE104 versus placebo changes in total score from baseline in Hamilton Anxiety Rating Scale (HAM-A)
Time Frame: Weeks 1, 2, 8 and 12
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Weeks 1, 2, 8 and 12
|
|
RE104 versus placebo percentage of participants with HAM-A response (≥50% reduction in score from Baseline)
Time Frame: Weeks 1, 2, 4, 8 and 12
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Weeks 1, 2, 4, 8 and 12
|
|
RE104 versus placebo percentage of participants with HAM-A remission (total score ≤7)
Time Frame: Day 1 and Weeks 1, 2, 4, 8 and 12
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Day 1 and Weeks 1, 2, 4, 8 and 12
|
|
RE104 versus placebo change from Baseline at Weeks 1, 2, 4, 8, and 12 in Hospital Anxiety and Depression Scale (HADS) depression subscore
Time Frame: Weeks 1, 2, 4, 8 and 12
|
The Hospital Anxiety and Depression Scale (HADS) is a self-reported scale measure the severity of depression and anxiety in patients with comorbid medical conditions. The scale consists of 14 items (7 for anxiety and 7 for depression), with a score ranging between 0 and 21 for the anxiety and depression subscales. |
Weeks 1, 2, 4, 8 and 12
|
|
RE104 versus placebo incidence of treatment-emergent adverse events (TEAEs) by frequency, severity and seriousness.
Time Frame: From dosing through study completion (post-dose follow-up is for 12 weeks)
|
A treatment-emergent adverse event (TEAE) is defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a study drug. |
From dosing through study completion (post-dose follow-up is for 12 weeks)
|
|
RE104 versus placebo change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) (Part B only)
Time Frame: Weeks 1, 2, 4, 8, and 12
|
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression. |
Weeks 1, 2, 4, 8, and 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Mark Pollack, M.D., Reunion Neuroscience Inc
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RE104-203-GAD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.